{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:48:47Z","timestamp":1782823727756,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.7759\/cureus.111809","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:31:14Z","timestamp":1782822674000},"source":"Crossref","is-referenced-by-count":0,"title":["The Bitter Aftertaste of Kratom: A Toxicologic and Neurologic Challenge"],"prefix":"10.7759","author":[{"given":"Aditya","family":"Lal Vallath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmitha","family":"Pippari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Deyulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Drug Enforcement Administration, Diversion Control Division, Drug and Chemical Evaluation Section. (2025). https.\/\/www.deadiversion.usdoj.gov\/drug\\_chem\\_info\/kratom.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.11.012","article-title":"From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction","volume":"37","author":"Hassan Z","year":"2013","unstructured":"Hassan Z, Muzaimi M, Navaratnam V, et al.. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013, 37:138-51. 10.1016\/j.neubiorev.2012.11.012","journal-title":"Neurosci Biobehav Rev"},{"key":"ref3","article-title":"Kratom in Thailand: Legislative Reform of Drug Policies (Briefing Paper No. 13)","author":"Tanguay P","year":"2011","unstructured":"Tanguay P. Kratom in Thailand: Legislative Reform of Drug Policies (Briefing Paper No. 13). Transnational Institute, 2011."},{"key":"ref4","article-title":"A fading Thai drug finds its resurgence in a cocktail","author":"Fuller T","year":"2012","unstructured":"Fuller T. A fading Thai drug finds its resurgence in a cocktail. New York Times. 2012,","journal-title":"New York Times"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107849","article-title":"Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic","volume":"208","author":"Garcia-Romeu A","year":"2020","unstructured":"Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020, 208:107849. 10.1016\/j.drugalcdep.2020.107849","journal-title":"Drug Alcohol Depend"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6814a2","article-title":"Notes from the field: unintentional drug overdose deaths with kratom detected - 27 states, July 2016-December 2017","volume":"68","author":"Olsen EO","year":"2019","unstructured":"Olsen EO, O'Donnell J, Mattson CL, Schier JG, Wilson N. Notes from the field: unintentional drug overdose deaths with kratom detected - 27 states, July 2016-December 2017. MMWR Morb Mortal Wkly Rep. 2019, 68:326-7. 10.15585\/mmwr.mm6814a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref7","unstructured":"NIDA. Kratom. National Institute on Drug Abuse website. (2022). Accessed. August 9, 2025: https:\/\/nida.nih.gov\/research-topics\/kratom."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00151-x","article-title":"Kratom-pharmacology, clinical implications, and outlook: a comprehensive review","volume":"9","author":"Eastlack SC","year":"2020","unstructured":"Eastlack SC, Cornett EM, Kaye AD. Kratom-pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020, 9:55-69. 10.1007\/s40122-020-00151-x","journal-title":"Pain Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229646","article-title":"Evaluating kratom alkaloids using PHASE","volume":"15","author":"Ellis CR","year":"2020","unstructured":"Ellis CR, Racz R, Kruhlak NL, et al.. Evaluating kratom alkaloids using PHASE. PLoS One. 2020, 15:e0229646. 10.1371\/journal.pone.0229646","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-015-1279-y","article-title":"The pharmacology and toxicology of kratom: from traditional herb to drug of abuse","volume":"130","author":"Warner ML","year":"2016","unstructured":"Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016, 130:127-38. 10.1007\/s00414-015-1279-y","journal-title":"Int J Legal Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2891","article-title":"Clinical assessment of the drug interaction potential of the psychotropic natural product kratom","volume":"113","author":"Tanna RS","year":"2023","unstructured":"Tanna RS, Nguyen JT, Hadi DL, et al.. Clinical assessment of the drug interaction potential of the psychotropic natural product kratom. Clin Pharmacol Ther. 2023, 113:1315-25. 10.1002\/cpt.2891","journal-title":"Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001290","article-title":"Prevalence of kratom use disorder among kratom consumers","volume":"18","author":"Hill K","year":"2024","unstructured":"Hill K, Grundmann O, Smith KE, Stanciu CN. Prevalence of kratom use disorder among kratom consumers. J Addict Med. 2024, 18:306-12. 10.1097\/ADM.0000000000001290","journal-title":"J Addict Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2015.1012610","article-title":"Social functioning of kratom (Mitragyna speciosa) users in Malaysia","volume":"47","author":"Singh D","year":"2015","unstructured":"Singh D, M\u00fcller CP, Vicknasingam BK, Mansor SM. Social functioning of kratom (Mitragyna speciosa) users in Malaysia. J Psychoactive Drugs. 2015, 47:125-31. 10.1080\/02791072.2015.1012610","journal-title":"J Psychoactive Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.03.017","article-title":"Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users","volume":"139","author":"Singh D","year":"2014","unstructured":"Singh D, M\u00fcller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014, 139:132-7. 10.1016\/j.drugalcdep.2014.03.017","journal-title":"Drug Alcohol Depend"},{"key":"ref15","article-title":"Pharmacotherapy for management of \"kratom use disorder\": a systematic literature review with survey of experts","volume":"120","author":"Stanciu C","year":"2021","unstructured":"Stanciu C, Ahmed S, Hybki B, Penders T, Galbis-Reig D. Pharmacotherapy for management of \"kratom use disorder\": a systematic literature review with survey of experts. WMJ. 2021, 120:54-61.","journal-title":"WMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.6339","article-title":"Kratom-related deaths","volume":"321","author":"Kuehn B","year":"2019","unstructured":"Kuehn B. Kratom-related deaths. JAMA. 2019, 321:1966. 10.1001\/jama.2019.6339","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6529a4","article-title":"Notes from the field: kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010-2015","volume":"65","author":"Anwar M","year":"2016","unstructured":"Anwar M, Law R, Schier J. Notes from the field: kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016, 65:748-9. 10.15585\/mmwr.mm6529a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119862530","article-title":"Characteristics of deaths associated with kratom use","volume":"33","author":"Corkery JM","year":"2019","unstructured":"Corkery JM, Streete P, Claridge H, et al.. Characteristics of deaths associated with kratom use. J Psychopharmacol. 2019, 33:1102-23. 10.1177\/0269881119862530","journal-title":"J Psychopharmacol"},{"key":"ref19","unstructured":"Food and Drug Administration. (2025). https.\/\/www.fda.gov\/news-events\/public-health-focus\/fda-and-kratom."},{"key":"ref20","article-title":"Key Substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22\u201107\u201101","author":"Substance Abuse and Mental Health Services Administration","year":"2022","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22\u201107\u201101. Substance Abuse and Mental Health Services Administration, 2022."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2018.12.038","article-title":"Motives for using Kratom (Mitragyna speciosa Korth.) among regular users in Malaysia","volume":"233","author":"Singh D","year":"2019","unstructured":"Singh D, Narayanan S, M\u00fcller CP, et al.. Motives for using Kratom (Mitragyna speciosa Korth.) among regular users in Malaysia. J Ethnopharmacol. 2019, 233:34-40. 10.1016\/j.jep.2018.12.038","journal-title":"J Ethnopharmacol"},{"key":"ref22","unstructured":"Not all kratom is equal. The important distinction between native leaf and extract products. (2025). https:\/\/globalkratomcoalition.org\/the-kratom-consumer-hub\/not-all-kratom-is-equal-the-important-distinction-between-n...."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11060789","article-title":"Lyme neuroborreliosis: mechanisms of B. burgdorferi infection of the nervous system","volume":"11","author":"Ford L","year":"2021","unstructured":"Ford L, Tufts DM. Lyme neuroborreliosis: mechanisms of B. burgdorferi infection of the nervous system. Brain Sci. 2021, 11:10.3390\/brainsci11060789","journal-title":"Brain Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.2.1014-1022.2005","article-title":"Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier","volume":"73","author":"Grab DJ","year":"2005","unstructured":"Grab DJ, Perides G, Dumler JS, et al.. Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier. Infect Immun. 2005, 73:1014-22. 10.1128\/IAI.73.2.1014-1022.2005","journal-title":"Infect Immun"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2119\/2007-00091.Rupprecht","article-title":"The pathogenesis of lyme neuroborreliosis: from infection to inflammation","volume":"14","author":"Rupprecht TA","year":"2008","unstructured":"Rupprecht TA, Koedel U, Fingerle V, Pfister HW. The pathogenesis of lyme neuroborreliosis: from infection to inflammation. Mol Med. 2008, 14:205-12. 10.2119\/2007-00091.Rupprecht","journal-title":"Mol Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105838","article-title":"3D blood-brain barrier-organoids as a model for Lyme neuroborreliosis highlighting genospecies dependent organotropism","volume":"26","author":"Adams Y","year":"2023","unstructured":"Adams Y, Clausen AS, Jensen P\u00d8, et al.. 3D blood-brain barrier-organoids as a model for Lyme neuroborreliosis highlighting genospecies dependent organotropism. iScience. 2023, 26:105838. 10.1016\/j.isci.2022.105838","journal-title":"iScience"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-015-0039-0","article-title":"Programmed cell death and its role in inflammation","volume":"2","author":"Yang Y","year":"2015","unstructured":"Yang Y, Jiang G, Zhang P, Fan J. Programmed cell death and its role in inflammation. Mil Med Res. 2015, 2:12. 10.1186\/s40779-015-0039-0","journal-title":"Mil Med Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8346-2","article-title":"Neuroborreliosis","volume":"264","author":"Halperin JJ","year":"2017","unstructured":"Halperin JJ. Neuroborreliosis. J Neurol. 2017, 264:1292-7. 10.1007\/s00415-016-8346-2","journal-title":"J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006978.pub2","article-title":"Antibiotics for the neurological complications of Lyme disease","volume":"12","author":"Cadavid D","year":"2016","unstructured":"Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the neurological complications of Lyme disease. Cochrane Database Syst Rev. 2016, 12:CD006978. 10.1002\/14651858.CD006978.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482017-the-bitter-aftertaste-of-kratom-a-toxicologic-and-neurologic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:31:27Z","timestamp":1782822687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482017-the-bitter-aftertaste-of-kratom-a-toxicologic-and-neurologic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.111809","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}